Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here


Kidney knowledge base featuring commentary on clinical trials.

Commentaries from Professor Susanne Osanto on current clinical trials within Renal Cell Carcinoma

Updates to these commentaries and further trials will be commented on over the coming months.

Latest update 10th April 2014

Since 2005 we witnessed an unprecedented progress in the treatment of advanced RCC. Several targeted therapies have become available for first- and second-line use including sorafenib, sunitinib, bevacizumab (plus IFN-α), temsirolimus, everolimus, pazopanib, and, most recently, axitinib. The currently approved drugs, most of which are oral compounds, are given continuously but treatment resistance will occur eventually. Developing a better understanding of primary and acquired mechanisms of resistance and feedback responses are critical for rational drug and combination therapy development. Most of the targeted therapies to date provide only temporary responses due to emergence of resistance. For that reason, combination strategies were anticipated to more likely have better outcomes. But thus far, combination strategies have failed in RCC.

As there are no new other classes of drugs registered (yet) for the treatment of advanced RCC, remaining open questions with regard to superiority or non-inferiority of single agents or combinations in first-line or second-line have been addressed in the latest trials presented in the second half of 2013 and in 2014. Another relevant question was the best sequence to use currently available drugs. 

In mRCC trials, progression-free survival (PFS) has been used as primary endpoint and PFS served as the basis of approval for several targeted therapies. However, as overall survival data are emerging from more recent trials, whether the optimal sequence of first-line, second-line and third-line choices in relation to costs and quality of life (toxicity of compounds and co-morbidity of the patients) becomes very important. 

Thus, ongoing and future challenges include the investigation of rational ways to sequence or combine current and new agents. But most importantly, there is an unmet need for novel classes of effective agents.

Kidney Cancer News from ASCO 2014

Commentaries from Susanne Osanto on a selection of presentations within Kidney Cancer from this year’s ASCO meeting.

EAU 2017 Scientific Programme and Sessions

View the Scientific Programme and Sessions of the 2017 EAU Annual Congress, Munich, Germany.